Abstract: Disclosed herein is a cell-based assay for determining potency of a recombinant viral vector expressing a transgene.

Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.

Abstract: The present invention relates to nucleic acids. In particular, it relates to aptamers capable of binding to a flavivirus structural protein or a flavivirus non-structural protein, useful as therapeutics for preventing, treating and/or diagnosing a flavivirus infection in a patient.

Abstract: Disclosed are methods of screening a library of molecules to identify or select one or more molecules which selectively bind to a fused protein, or fragment thereof. The fused protein comprises a moiety and a protein selected from a group consisting of flavivirus structural and non-structural (NS) proteins. The method comprises contacting the library of molecules with the fused protein and detecting binding of one or more molecules to the fused protein.

Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.

Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.

Abstract: The present invention relates to a fused protein. In particular, it relates to biotinylated protein comprising a protein selected from a group consisting of flavivirus structural and non-structural (NS) proteins.

Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.

Abstract: A method comprising, sending an instruction from a validator member of a sysplex to a second member of a sysplex to prevent operations that alter a sysplex namespace, determining whether the validator member of the sysplex is communicative with the second member of the sysplex and whether the members of the sysplex retain current sysplex status information, sending an instruction from the validator member to the second member to send a first namespace attribute data associated with the second member to the validator member responsive to determining that the validator member of the sysplex is communicative with the second member of the sysplex and the members of the sysplex retain current sysplex status information, determining whether the first namespace attribute data associated with the second member is consistent with a second namespace attribute data, and sending an instruction to correct the first namespace attribute data.

Abstract: A method comprising, sending an instruction from a validator member of a sysplex to a second member of a sysplex to prevent operations that alter a sysplex namespace, determining whether the validator member of the sysplex is communicative with the second member of the sysplex and whether the members of the sysplex retain current sysplex status information, sending an instruction from the validator member to the second member to send a first namespace attribute data associated with the second member to the validator member responsive to determining that the validator member of the sysplex is communicative with the second member of the sysplex and the members of the sysplex retain current sysplex status information, determining whether the first namespace attribute data associated with the second member is consistent with a second namespace attribute data, and sending an instruction to correct the first namespace attribute data.

Abstract: A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions.